HUMANIGEN | NEUTRAL vs. BUY | USD17 VS. USD35 Anticipating more clarity on the regulatory path forward for lenzilumab
HUMANIGEN | NEUTRAL vs. BUY | USD17 VS. USD35Anticipating more clarity on the regulatory path forward for lenzilumab
FDA declined the EUA application for lenzilumab in COVID-19
Potential regulatory path forward for lenzilumab in COVID-19 in the US
Lenzilumab’s potential beyond COVID-19
Awaiting for more clarity in COVID-19, we lower TP to USD17 and downgrade to Neutral
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.